|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study used a rat model to test whether prenatal immune activation with lipopolysaccharide (LPS; at gestation days, GD, 15 and 16) or maternal iron deficiency (from GD2 to postnatal day P7) or the combination of both insults alters major subtypes of GABAergic interneurons (parvalbumin, somatostatin, cholecystokinin) in brain regions relevant to schizophrenia (medial and dorsolateral prefrontal cortex [PFC], hippocampal CA1 and dentate gyrus, ventral subiculum) in offspring at P14 or P28.
|
28214898 |
2016 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients.
|
20732371 |
2010 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that schizophrenia is associated with alterations in inhibitory inputs from SST/NPY-containing and CCK-containing subpopulations of GABA neurons and in the signaling via certain GABA(A) receptors that mediate synaptic (phasic) or extrasynaptic (tonic) inhibition.
|
17471287 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
These findings suggest that schizophrenia is associated with alterations in inhibitory inputs from SST/NPY-containing and CCK-containing subpopulations of GABA neurons and in the signaling via certain GABA(A) receptors that mediate synaptic (phasic) or extrasynaptic (tonic) inhibition.
|
17471287 |
2008 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This combination of findings suggests the testable hypothesis that reduced CB1R mRNA and protein levels in schizophrenia represent a compensatory mechanism to increase GABA transmission from perisomatic-targeting cholecystokinin interneurons with impaired GABA synthesis.
|
18606950 |
2008 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
While our family-based tests seem to support the CCK involvement in schizophrenia, no definite conclusion can be drawn based on such a small sample size.
|
12116180 |
2002 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia.
|
11549403 |
2001 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The tetrapeptide of cholecystokinin (CCK), CCK-4, is known to induce panic attacks in human subjects, while CCK-8 is reported to have a therapeutic effect on schizophrenia symptoms.
|
11803530 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia.
|
11549403 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia.
|
11443535 |
2001 |
|
Schizophrenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder.
|
9491815 |
1998 |
|
Schizophrenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
In so far as CCK is co-localized with GABA or glutamate in cortical neurons, both of these neuronal populations need to be studied further in schizophrenia and suicide.
|
9278188 |
1997 |
|
Schizophrenia
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The study revealed a marked decrease in CCK mRNA of 83% in frontal cortex (BA10) and 63% in superior temporal cortex (BA22) in schizophrenia with no change in G(o) alpha-subunit mRNA in either region.
|
7640324 |
1995 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to analyse the function of cholecystokinin octapeptide (CCK-8) during induced pancreatitis in an animal model.
|
31171354 |
2020 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
BEFREE |
I performed research on the relationship between exocrine and endocrine aspects of the pancreas, pancreatic exocrine functions in diabetes mellitus, the role of cholecystokinin (CCK) and its synthetic analogue on exocrine and endocrine pancreas function, the role of CCK on the pathogenesis of pancreatitis, the cellular mechanisms of reversible and irreversible pancreatitis, and pancreatic stellate cell activation.
|
28506430 |
2019 |
|
Pancreatitis
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that activation of the CCK receptor contributes to pancreatitis and blockade of this pathway would improve chronic pancreatitis.
|
31598921 |
2019 |
|
Pancreatitis
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
This reduced basolateral exocytosis in part explained the less severe pancreatitis observed in Munc18c<sup>+/-</sup> mice after hyperstimulation with the CCK-8 analog caerulein.
|
29284677 |
2018 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
BEFREE |
Exogenous CCK administration has been used in animal models to study pancreatitis and also as a promoter of carcinogen-induced or Kras-driven pancreatic cancer.
|
24177032 |
2014 |
|
Pancreatitis
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
However, the clinical relevance of CCK as a trigger factor has to be questioned, as it is difficult to envisage a situation in humans where abnormally high levels of CCK would be released into the circulation to trigger pancreatitis in alcoholics.
|
18336667 |
2008 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
CTD_human |
The aim of our study was to test the effects of resveratrol pretreatment on cholecystokinin-octapeptide (CCK-8)-induced acute pancreatitis in rats.
|
16499907 |
2006 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
CTD_human |
Cholecystokinin (CCK), which induces pancreatitis, stimulates CrkII tyrosine phosphorylation and CrkII protein complexes, raising the possibility it can be important in the acinar cell responses to ROS.
|
16187300 |
2006 |
|
Pancreatitis
|
0.370 |
Biomarker
|
disease |
BEFREE |
Impaired activation of pancreatic proteases in the small intestine is perceived as the pivotal problem that leads to continual feedback release of cholecystokinin, thus, in effect, causing a chronic hyperstimulation pancreatitis with intra-acinar activation of zymogens and, when bicarbonate secretion falls, precipitation of 'Reg' and other proteins in the duct system.
|
9832635 |
1998 |
|
Anorexia
|
0.360 |
Biomarker
|
disease |
BEFREE |
They can show an increase in phosphorylated Stat-3 in the presence of leptin, are electrically excited by the anorectic neuromodulator cholecystokinin, and inhibited by orexigenic neuromodulators neuropeptide Y, met-enkephalin, dynorphin and the catecholamine dopamine.
|
30618146 |
2019 |
|
Anorexia
|
0.360 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that both GLP-1 and CCK play contributory roles in T-2 toxin-induced anorexia.
|
29433086 |
2018 |
|
Anorexia
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
However, the GD score and serum GAS, CCK, and MTL levels in the acute LF group were not statistically different, when compared with those in the subacute LF group, acute-on-chronic LF group and chronic LF group.LF plays a key role in the development of GD, and may be the main cause of obvious gastrointestinal symptoms, such as abdominal distension, nausea, vomiting and anorexia, in LF patients.
|
30508896 |
2018 |